BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape

Kristen K. Ciombor, John H. Strickler, Tanios S. Bekaii-Saab, Rona Yaeger

Research output: Contribution to journalReview articlepeer-review


BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this tumor type on the basis of prognostic and predictive implications. BRAF alterations in colorectal cancer are classified into three functional categories on the basis of signaling mechanisms, with the class I BRAFV600E mutation occurring most frequently in colorectal cancer. Functional categorization of BRAF mutations in colorectal cancer demonstrates distinct mitogen-activated protein kinase pathway signaling. On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAFV600E-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced colorectal cancer.

Original languageEnglish (US)
Article numberJCO.21.02541
JournalJournal of Clinical Oncology
StatePublished - May 1 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape'. Together they form a unique fingerprint.

Cite this